80 related articles for article (PubMed ID: 8100640)
1. Adrenergic and non-adrenergic vasoconstrictor mechanisms in the human nasal mucosa.
Fischer L; Auberson S; Bretton C; Lacroix JS
Rhinology; 1993 Mar; 31(1):11-5. PubMed ID: 8100640
[TBL] [Abstract][Full Text] [Related]
2. Adrenergic and non-adrenergic mechanisms in sympathetic vascular control of the nasal mucosa.
Lacroix JS
Acta Physiol Scand Suppl; 1989; 581():1-63. PubMed ID: 2568728
[TBL] [Abstract][Full Text] [Related]
3. Vascular control of the pig nasal mucosa: distribution and effect of somatostatin in relation to noradrenaline and neuropeptide Y.
Lacroix JS; Auberson S; Morel DR; Theodorsson E; Hökfelt T; Lundberg JM
Regul Pept; 1992 Aug; 40(3):373-87. PubMed ID: 1359611
[TBL] [Abstract][Full Text] [Related]
4. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control.
Pernow J
Acta Physiol Scand Suppl; 1988; 568():1-56. PubMed ID: 3232527
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane.
Fabi F; Argiolas L; Ruvolo G; del Basso P
Br J Pharmacol; 1998 May; 124(1):101-10. PubMed ID: 9630349
[TBL] [Abstract][Full Text] [Related]
6. Synergism between neuropeptide Y and norepinephrine highlights sympathetic cotransmission: studies in rat arterial mesenteric bed with neuropeptide Y, analogs, and BIBP 3226.
Cortés V; Donoso MV; Brown N; Fanjul R; López C; Fournier A; Huidobro-Toro JP
J Pharmacol Exp Ther; 1999 Jun; 289(3):1313-22. PubMed ID: 10336522
[TBL] [Abstract][Full Text] [Related]
7. Sympathetic vascular control of the pig nasal mucosa (2): Reserpine-resistant, non-adrenergic nervous responses in relation to neuropeptide Y and ATP.
Lacroix JS; Stjärne P; Anggård A; Lundberg JM
Acta Physiol Scand; 1988 Jun; 133(2):183-97. PubMed ID: 3227914
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension.
Wiest R; Jurzik L; Moleda L; Froh M; Schnabl B; von Hörsten S; Schölmerich J; Straub RH
J Hepatol; 2006 Mar; 44(3):512-9. PubMed ID: 16324766
[TBL] [Abstract][Full Text] [Related]
9. Sympathetic vascular control of the pig nasal mucosa (III): Co-release of noradrenaline and neuropeptide Y.
Lacroix JS; Stjärne P; Anggärd A; Lundberg JM
Acta Physiol Scand; 1989 Jan; 135(1):17-28. PubMed ID: 2911948
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y and non-adrenergic sympathetic vascular control of the cat nasal mucosa.
Lundblad L; Anggard A; Saria A; Lundberg JM
J Auton Nerv Syst; 1987 Oct; 20(3):189-97. PubMed ID: 3693801
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y stimulates DNA synthesis in human vascular smooth muscle cells through neuropeptide Y Y1 receptors.
Nilsson T; Edvinsson L
Can J Physiol Pharmacol; 2000 Mar; 78(3):256-9. PubMed ID: 10721818
[TBL] [Abstract][Full Text] [Related]
13. The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Br J Pharmacol; 1997 Jun; 121(3):595-603. PubMed ID: 9179405
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney.
Oellerich WF; Malik KU
J Pharmacol Exp Ther; 1993 Sep; 266(3):1321-9. PubMed ID: 8371140
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries.
Edvinsson L
Acta Physiol Scand; 1985 Sep; 125(1):33-41. PubMed ID: 2864784
[TBL] [Abstract][Full Text] [Related]
16. In vivo receptor characterization of neuropeptide Y-induced effects in consecutive vascular sections of cat skeletal muscle.
Ekelund U; Erlinge D
Br J Pharmacol; 1997 Feb; 120(3):387-92. PubMed ID: 9031740
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action.
Wahlestedt C; Edvinsson L; Ekblad E; Håkanson R
J Pharmacol Exp Ther; 1985 Sep; 234(3):735-41. PubMed ID: 3928874
[TBL] [Abstract][Full Text] [Related]
18. Use of D-myo inositol 1,2,6 trisphosphate to inhibit contractile activity in rat ventricular cardiomyocytes induced by neuropeptide Y and other cardioactive peptides through phospholipase C.
Bell D; Millar BC; McDermott BJ
Br J Pharmacol; 1997 Dec; 122(8):1655-60. PubMed ID: 9422811
[TBL] [Abstract][Full Text] [Related]
19. Adrenergic and neuropeptide Y supersensitivity in denervated nasal mucosa vasculature of the pig.
Lacroix JS; Lundberg JM
Eur J Pharmacol; 1989 Oct; 169(1):125-36. PubMed ID: 2599007
[TBL] [Abstract][Full Text] [Related]
20. Coronary vasoconstrictive effects of neuropeptide Y and their modulation by the ATP-sensitive potassium channel in anesthetized dogs.
Tanaka E; Mori H; Chujo M; Yamakawa A; Mohammed MU; Shinozaki Y; Tobita K; Sekka T; Ito K; Nakazawa H
J Am Coll Cardiol; 1997 May; 29(6):1380-9. PubMed ID: 9137239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
